

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 10, 2008

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-33609

13-3929237

(State or Other Juris-
diction of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4520 East-West Highway, Suite 300
Bethesda, Maryland

20814

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective October 10, 2008, Stanley G. Miele was appointed as the registrant's Senior Vice President, Sales and Marketing.

Mr. Miele has over eighteen years of sales and marketing experience in the pharmaceutical and medical device industries. He joined Sucampo in February 2006 as Director, National Sales and was promoted to Vice President, Sales in October 2007. During that time, he worked with senior management to hire and train a 38-person sales force that sells AMITIZA® into the Long-Term Care and Hospital segments of the U.S. constipation market. Sucampo co-markets AMITIZA with Takeda Pharmaceutical North America. Prior to joining Sucampo, Mr. Miele managed a national team of specialty sales representatives and engineering consultants that sold and marketed blood gas analyzers and point of care diagnostic equipment used in acute-care areas within hospitals. Prior to that, Mr. Miele held a series of positions at Millennium Pharmaceuticals (and COR Therapeutics prior to its acquisition by Millennium) including National Sales Director, Cardiology where he was responsible for managing the overall hospital-based cardiovascular sales function. This position included the promotion and marketing of Integrilin, for which he assisted in the design of marketing materials and the launch of an office-based cardiovascular sales team. Previously, Mr. Miele was a Division Sales Representative with Abbott Labs' Hospital Products Division, of Abbott Park, Illinois, and a Sales Representative for Syntex Labs, of Palo Alto, California. Mr. Miele earned a B.A. in Management/Communications from the University of Dayton.

On October 10, 2008, the registrant and Brad E. Fackler, the current Executive Vice President of Commercial Operations of the registrant, agreed that he will resign from his position as an executive officer of the registrant effective immediately. Mr. Fackler has agreed to remain as an employee at Sucampo for a period of time to assist in the transition of responsibilities. Pursuant to his employment agreement with the registrant, Mr. Fackler will be entitled to severance equal to six months of his base salary, payable in a lump sum at the end of his employment, and six months of reimbursement for the cost of continued health insurance coverage.

The press release issued in connection with Mr. Miele's appointment to Senior Vice President, Sales and Marketing and Mr. Fackler's departure is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

- 99.1 Press Release issued by the registrant on October 16, 2008 announcing the appointment of Stanley G. Miele as the registrant's Senior Vice President, Sales and Marketing.
-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: October 17, 2008

By: /s/ JAN SMILEK

Name: Jan Smilek

Title: Acting Chief Financial Officer



FOR IMMEDIATE RELEASE

Contact:

Kate de Santis

Sucampo Pharmaceuticals, Inc.

240-223-3834

Or

John Woolford

Westwicke Partners, LLC

443-213-0506

john.woolford@westwickepartners.com

Sucampo Names Stanley G. Miele Head of Sales & Marketing

Brad E. Fackler to Leave Sucampo

Bethesda, Md, October 16, 2008 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the promotion of Stanley G. Miele to Senior Vice President, Sales & Marketing, effective October 13, 2008. Mr. Miele will report directly to Ryuji Ueno, M.D., Ph.D., Chairman and Chief Executive Officer, and will be responsible for Sucampo's Sales & Marketing, as well as its Business Development, efforts.

Dr. Ueno said, "We are very pleased to select Stan to head Sucampo's Sales & Marketing and Business Development efforts. His implementation of a device-based marketing and selling strategy has been key to our success in the long-term care pharmaceutical setting. During his tenure here at Sucampo, Stan demonstrated his ability to lead the team and drive sales growth. His strong implementation skills and leadership capabilities have contributed to Sucampo's presence in the Long Term Care and Geriatric market, which is reflected in being ranked as a top 20 pharmaceutical company in promoting to the U.S. nursing home market in a Spring 2007 Verispan survey.¹"

Mr. Miele has over eighteen years of sales and marketing experience in the pharmaceutical and medical device industries. He joined Sucampo in February 2006 as Director, National Sales and was promoted to Vice President, Sales in October 2007. During that time, he worked with senior management to hire and train a 38-person sales force that sells AMITIZA® into the Long-Term Care and Hospital segments of the U.S. constipation market. Sucampo co-markets AMITIZA with Takeda Pharmaceutical North America. Prior to joining Sucampo, Mr. Miele managed a national level team of specialty sales representatives and engineering consultants that sold and marketed blood gas analyzers and point of care diagnostic equipment used in acute-care areas within hospitals. Prior to that, Mr. Miele held a series of positions at Millennium Pharmaceuticals (and COR Therapeutics prior to its acquisition by Millennium) including

National Sales Director, Cardiology where he was responsible for managing the overall hospital-based cardiovascular sales function. This position included the promotion and marketing of Integrilin, for which he assisted in the design of marketing materials and the launch of an office-based cardiovascular sales team. Previously, Mr. Miele was a Division Sales Representative with Abbott Labs' Hospital Products Division, of Abbott Park, Illinois, and a Sales Representative for Syntex Labs, of Palo Alto, California. Mr. Miele earned a B.A. in Management/Communications from the University of Dayton.

Sucampo Pharmaceuticals today also announced that Brad E. Fackler, Executive Vice President, Commercial Operations, will leave the organization. He has agreed to remain at Sucampo for a period of time to assist in the transition of responsibilities.

Dr. Ueno said, "Brad Fackler has been instrumental in Sucampo's evolution from a research and development organization into a commercial company selling an F.D.A. approved product. He played a key role in AMITITZA's launch through the selection of the Long-Term Care market segment, as a strategic focus for Sucampo's sales and marketing efforts."

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and Advisor, International Business Development.

Sucampo Pharmaceuticals is marketing AMITIZA® (lubiprostone) 24 mcg in the U.S. for Chronic Idiopathic Constipation in adults and AMITIZA 8 mcg in the U.S. to treat Irritable Bowel Syndrome with Constipation in adult women. Sucampo is also developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK, with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com

AMITIZA® is a registered trademark of Sucampo Pharmaceuticals, Inc.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors described in Sucampo Pharmaceuticals'

filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2007 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Footnote:

1. Source: Verispan Spring 2007 Nursing Home Provider Survey.

###